Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients

Journal of Infectious Diseases

Volumn 173, Issue 1, 1996, Pages 219-225

  Maenza, Janine R ^a   Keruly, Jeanne C ^a   Moore, Richard D ^a   Chaisson, Richard E ^a   Merz, William G ^a   Gallant, Joel E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CLOTRIMAZOLE; DIDANOSINE; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; NYSTATIN; PENTAMIDINE; PYRROLE DERIVATIVE; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CANDIDIASIS; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG USE; ESOPHAGITIS; FEMALE; FUNGAL MENINGITIS; FUNGUS CULTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; MEDICAL RECORD; MINIMUM INHIBITORY CONCENTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK FACTOR; THRUSH; TOPICAL DRUG ADMINISTRATION;

EID: 0030042222     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.1.219     Document Type: Article

References (24)

1. Selik RM, Starcher ET, Curran AV. Opportunistic diseases reported in AIDS patients: frequencies, associations, and trends. AIDS 1987;1: 175-82.
2. Chavenet P, Lopez J, Grappin M, et al. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients. AIDS 1994;8:945-50.
3. Vuffray A, Durussel C, Boerlin P, et al. Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients [letter]. AIDS 1994;8:708-9.
4. Troillet N, Durussel C, Bille J, Glauser MP, Chave JP. Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant Oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis 1993;12:911-5.
5. Boken DJ, Swindells S, Rinaldi MG. Fluconazole-resistant Candida albicans. Clin Infect Dis 1993;17:1018-21.
6. Redding S, Smith J, Farinacci G, et al. Resistance of Candida albicans to fluconazole during treatment of Oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis 1994;18:240-2.
7. Cameron ML, Schell WA, Bruch S, Bartlett JA, Waskin HA, Perfect JR. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother 1993;37:2449-53.
8. Newman SL, Flanigan TP, Fisher A, Rinaldi MG, Stein M, Vigilante K. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis 1994;19:684-6.
9. White A, Goetz MB. Azole-resistant Candida albicans: report of two cases of resistance to fluconazole and review. Clin Infect Dis 1994;19: 687-92.
10. Bailey GG, Perry FM, Denning DW, Mandal BK. Fluconazole-resistant candidosis in an HIV cohort. AIDS 1994;8:787-92.
11. Sangeorzan JA, Bradley SF, Xiaogang H, et al. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994;97:339-46.
12. Sanguineti A, Carmichael K, Campbell K. Fluconazole-resistant Candida albicans after long-term suppressive therapy. Arch Intern Med 1993;153:1122-4.
13. Millon L, Manteaux A, Reboux G, et al. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype. J Clin Microbiol 1994;32:1115-8.
14. Heald A, Cox G, Schell W, Bartlett J, Miralles D, Perfect J. Oropharyngeal yeast flora in human immunodeficiency virus infected patients receiving long-term continuous fluconazole therapy [abstract 1-227]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994.
15. Chaisson RE, Stanton DL, Gallant JE, Rucker S, Bartlett JG, Moore RD. Impact of the 1993 revision of the AIDS case definition on the prevalence of AIDS in a clinical setting. AIDS 1993;7:857-62.
16. Moore RD, Stanton D, Gopalan R, Chaisson RE. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med 1994;330:763-8.
17. Nolan A, Lamey PJ, Macfarlane TW, Aitchison TC, Shaw J, Sirell JY. The effect of nebulised pentamidine on the concentration of infra-oral Candida albicans in HIV-infected patients. J Med Microbiol 1994; 41:95-7.
18. St Germain G. Effects of pentamidine alone and in combination with ketoconazole or itraconazole on the growth of Candida albicans. Antimicrob Agents Chemother 1990;34:2304-6.
19. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts: proposed standard. Villanova, PA: NCCLS, 1992; document M27-P.
20. Powderly WG. Mucosal candidiasis caused by non-albicans species of Candida in HIV-positive patients. AIDS 1992;6:604-5.
21. Dronda F, Chaves F, Alonso-Sanz M, et al. Clinical significance of mixed oropharyngeal candidiasis due to Candida albicans and non-albicans strains in HIV-infected patients [abstract I-215]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994.
22. Pfaller MA, Rhine-Chalberg J, Redding SW, et al. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol 1994;32:59-64.
23. Powderly WG, Robinson K, Keath EI. Molecular epidemiology of recurrent oral candidiasis in human immunodeficiency virus-positive patients: evidence for two patterns of recurrence. J Infect Dis 1993;168:463-6.
24. Bodey GP. Azole antifungal agents. Clin Infect Dis 1992;14(suppl 1):S161-9.